Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 56, Issue 3, pp 231–238 | Cite as

Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?

  • Ronald de Wit
  • Matti Aapro
  • Peter R Blower
Review

Abstract

5-HT3-receptor antagonists are the current antiemetic ‘gold standard’ for chemotherapy- and radiotherapy-induced nausea and vomiting. Interestingly, studies have shown that patients experiencing poor control of acute chemotherapy-induced nausea and vomiting with one antiemetic therapy may respond well to another agent, including a drug of the same class. This review examines pharmacological differences between the 5-HT3-receptor antagonists in order to determine potential reasons for their differing efficacy, particularly in relation to refractory emesis. Differences in drug metabolism by the cytochrome P450 system, inadequate dosing of the respective agents, differences in onset and duration of action, and effects on serotonin release and reuptake are discussed.

Keywords

5-HT3-receptor antagonists Chemotherapy-induced nausea and vomiting Refractory emesis 

Notes

Acknowledgements

This manuscript was supported by Roche.

References

  1. 1.
    ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery (1999). Am J Health Syst Pharm 56:729–764Google Scholar
  2. 2.
    Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, Kish JA, Murphy WK, Hainsworth JD, Gandara DR et al (1992) Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 10:1969–1975Google Scholar
  3. 3.
    Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ (1994) Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 38:557–566Google Scholar
  4. 4.
    Blower P, Aapro M (2002) Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade? Br J Cancer 86:1665–1666Google Scholar
  5. 5.
    Blower PR (2002) 5-HT3-receptor antagonist and the cytochrome P450 system: clinical implications. Cancer J 8:405–414Google Scholar
  6. 6.
    Bosnjak SM, Neskovic-Konstantinovic ZB, Jovanovic-Micic DJ, Mitrovic LB, Radulovic SS (1996) Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. J Chemother 8:315–318Google Scholar
  7. 7.
    Bruntsch U, Rufenacht E, Parker I, Drechsler S, de Bruijn K (1993) Tropisetron in the prevention of chemotherapy-induced nausea and vomiting in patients responding poorly to previous conventional antiemetic therapy. Ann Oncol 4(Suppl 3):25–29Google Scholar
  8. 8.
    Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramontes BE, McKinzie S, Urrutia R (2002) Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 123:425–432Google Scholar
  9. 9.
    Camilleri M, Mayer EA, Drossman DA, Heaths A, Dukes GE, McSorleys D, Kong S, Mangel AW, Northcutt AR (1999) Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 13:1149–1159Google Scholar
  10. 10.
    Carmichael J, Keizer HJ, Cupissol D, Milliez J, Scheidel P, Schindler AE (1998) Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs 9:381–385Google Scholar
  11. 11.
    Castejon AM, Paez X, Hernandez L, Cubeddu LX (1999) Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron. J Pharmacol Exp Ther 291:960–966Google Scholar
  12. 12.
    Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL (1990) Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322:810–816Google Scholar
  13. 13.
    Davis MP, Homsi J (2001) The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer 9:442–451Google Scholar
  14. 14.
    de Wit R (2003) Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics. Br J Cancer 88:1823–1827Google Scholar
  15. 15.
    de Wit R, de Boer AC, Linden GHM, Stoter G, Sparreboom A, Verweij J (2001) Effective crossover to granisetron after failure to ondansetron, a randomized double-blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer 85:1099–1101Google Scholar
  16. 16.
    Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR, Tarbit MH (1995) Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 23:1225–1230Google Scholar
  17. 17.
    Doherty KM (1999) Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Onc Nurs 3:113–119Google Scholar
  18. 18.
    Endo T, Hamaue N, Ihira E, Teramoto Y, Liu Y, Hirafuji M, Minami M (2002) Effects of granisetron, a 5-HT3 receptor antagonist, on 5-hydroxytryptamine (5-HT) release from the isolated ileum in a delayed-emesis rat model. Res Commun Mol Pathol Pharmacol 111:55–68Google Scholar
  19. 19.
    Endo T, Minami M, Hirafuji M, Ogawa T, Akita K, Nemoto M, Saito H, Yoshioka M, Parvez SH (2000) Neurochemistry and neuropharmacology of emesis–the role of serotonin. Toxicology 153:189–201Google Scholar
  20. 20.
    Endo T, Minami M, Kitamura N, Teramoto Y, Ogawa T, Nemoto M, Hamaue N, Hirafuji M, Yasuda E, Blower PR (1999) Effects of various 5-HT3 receptor antagonists, granisetron, ondansetron, ramosetron and azasetron on serotonin (5-HT) release from the ferret isolated ileum. Res Commun Mol Pathol Pharmacol 104:145–153Google Scholar
  21. 21.
    Endo T, Ogawa T, Hamaue N, Akita K, Hirafuji M, Minami M, Blower PR (1998) Granisetron, a 5-HT3 receptor antagonist, inhibited cisplatin-induced 5-hydroxytryptamine release in the isolated ileum of ferrets. Res Commun Mol Pathol Pharmacol 100:243–253Google Scholar
  22. 22.
    Endo T, Takahashi M, Minami M, Yoshioka M, Saito H, Parvez SH (1993) Effects of anticancer drugs on enzyme activities and serotonin release from ileal tissue in ferrets. Biol Amines 9:479–489Google Scholar
  23. 23.
    Farley PA, Shillington AC, Dempsey CL, Colgan K (2003) 5-HT3 antiemetic use in breast cancer patients receiving cyclophosphamide: a multicenter practice evaluation. Support Care Cancer 11:392 (Abstract A-20)Google Scholar
  24. 24.
    Feyer P (2002) Nausea und emesis in der Strahlntherapie. Im Focus Onkologie 8:64–68Google Scholar
  25. 25.
    Gandara DR, Roila F, Warr D, Edelman MJ, Perez EA, Gralla RJ (1998) Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration. Support Care Cancer 6:237–243Google Scholar
  26. 26.
    Gebauer A, Merger M, Kilbinger H (1993) Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Naunyn Schmiedebergs Arch Pharmacol 347:137–140Google Scholar
  27. 27.
    Gershon MD (2003) Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 3(Suppl 2):S25–S34Google Scholar
  28. 28.
    Gershon MD, Ross LL (1966) Radioisotopic studies of the binding, exchange, and distribution of 5-hydroxytryptamine synthesized from its radioactive precursor. J Physiol 186:451–476Google Scholar
  29. 29.
    Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, Einhorn L, Ettinger D, Bushnell W, Friedman C (1998) Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 16:1568–1573Google Scholar
  30. 30.
    Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971–2994Google Scholar
  31. 31.
    Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 29:1074–1080Google Scholar
  32. 32.
    Ihbe-Heffinger A, Kuhn W, Sattler D, Thödtmann J, Graeff, Bernard R (2000) Cost-minimization analysis for the use of 5-HT3-receptor antagonists in moderately emetogenic chemotherapy. A prospective pharmacoeconomic evaluation in German hospitals. Eur J Cancer 36:Abstract PP30Google Scholar
  33. 33.
    Inoue T, Kusumi I, Yoshioka M (2002) Serotonin transporters. Curr Drug Target CNS Neurol Disord 1:519–529Google Scholar
  34. 34.
    Italian Group for Antiemetic Research (1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6:805–810Google Scholar
  35. 35.
    Jann MW, Cohen LJ (2000) Ethnicity and antidepressant pharmacogenetics. Drug Metabol Drug Interact 16:39–67Google Scholar
  36. 36.
    Jantunen IT, Muhononen TT, Kataja VV, Flander MK, Teerenhovi L (1993) 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—a randomised study. Eur J Cancer 29A:1669–1672Google Scholar
  37. 37.
    Jordan K, Hinke A, Grothey A, Schmoll H-J (2003) A meta-analysis comparing the available 5-HT3-receptor antagonists as prophylactic agents for acute chemotherapy-induced emesis. Support Care Cancer 11:394 (Abstract A-29)Google Scholar
  38. 38.
    Jordan K, Hinke A, Grothey A, Schmoll H-J (2004) A meta-analysis comparing the efficacy of five 5-HT3-receptor antagonists (5-HT3-RAs) for acute chemotherapy-induced emesis. Proc Am Soc Clin Oncol 23:737(Abstract 8048)Google Scholar
  39. 39.
    Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, Possinger K, Roots I, Brockmoller J (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805–2811Google Scholar
  40. 40.
    Krengli M, Lazzari R, Manara M (1996) The use of granisetron per os in radiotherapy-induced emesis. Minerva Med 87:605–608Google Scholar
  41. 41.
    Leslie RA, Reynolds DJM (1993) Neurotransmitters and receptors in the emetic pathway. In: Andrews PLR, Sanger GJ (eds) Emesis in anti-cancer treatment: mechanisms and treatment. Chapman& Hall Medical, London, pp 91–112Google Scholar
  42. 42.
    Lindley C, Blower P (2000) Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health Syst Pharm 57:1685–1697Google Scholar
  43. 43.
    MASCC (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811–819Google Scholar
  44. 44.
    Massidda B, Ionta MT (1996) Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor antagonist in moderately emetogenic chemotherapy. J Chemother 8:237–242Google Scholar
  45. 45.
    Minami M, Endo T, Nemoto M, Hamaue N, Hirafuji M, Monama Y, Yajima, Yoshioka M, Saitoh H (1995) How do toxic emetic stimuli cause 5-HT release in the gut and brain? In: Raynolds DJM (ed) Serotonin and the scientific basis of antiemetic therapy. Oxford Clinical Communications, Oxford, pp 68–76Google Scholar
  46. 46.
    Minton NA (1994) Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists. Br J Clin Pharmacol 37:525–530Google Scholar
  47. 47.
    Mitchell PL, Evans BD, Allan SG, Forgeson GV, Mak D, Neave L, Humm G, Langley G, Dickson D, Harvey VJ (1992) Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics. N Z Med J 105:73–75Google Scholar
  48. 48.
    Navari RM, Kaplan HG, Gralla RJ, Grunberg SM, Palmer R, Fitts D (1994) Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 12:2204–2210Google Scholar
  49. 49.
    Newberry N, Watkins C, Sprosen T, Blackburn T, Grahame-Smith D, Leslie R (1993) BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors. Neuropharmacology 32:729–735Google Scholar
  50. 50.
    Numbenjapon T, Sriswasdi C, Mongkonsritragoon W, Leelasiri A, Prayoonwiwat W (2002) Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin’s lymphoma. J Med Assoc Thai 85:1156–1163Google Scholar
  51. 51.
    Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16:754–760Google Scholar
  52. 52.
    Roila F (1996) Control of acute cisplatin-induced emesis over repeat courses of chemotherapy. Italian Group for Antiemetic Research. Oncology 53:65–7252Google Scholar
  53. 53.
    Roila F, Del Favero A (1995) Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 29:95–109Google Scholar
  54. 54.
    Ruff P, Paska W, Goedhals L, Pouillart P, Riviere A, Vorobiof D, Bloch B, Jones A, Martin C, Brunet R et al (1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 51:113–118Google Scholar
  55. 55.
    Schnell FM (2003) Chemotherapy-induced nausea and vomiting–the importance of acute antiemetic control. Oncologist 8:187–198Google Scholar
  56. 56.
    Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Sevelda P, Christmann D, Schmidt M, Kitchener H, Paes D et al (1992) Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer 66:192–197Google Scholar
  57. 57.
    Terrey J-P, Aapro MS (1996) The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res 8:281–288Google Scholar
  58. 58.
    Tsavaris N, Kosmas CH, Vadiaka M, Kontos A, Katsorida M, Dimitrakopoulos A, Zerai A, Koufos CH (2001) Efficacy of ondansetron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study. J Exp Clin Cancer Res 20:29–34Google Scholar
  59. 59.
    Yalçin S, Tekuzman G, Baltali E, Özişik Y, Barişta I (1999) Serotonin antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy. A randomized study. Am J Clin Oncol 22:94–96Google Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.Rotterdam Cancer InstituteRotterdamThe Netherlands
  2. 2.Clinique de GenolierGenolierSwitzerland
  3. 3.Poole House, Great YeldhamEssexUK

Personalised recommendations